Prelude Therapeutics (PRLD) Other Non-Current Liabilities (2019 - 2026)

Prelude Therapeutics has reported Other Non-Current Liabilities for 7 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 8.22% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 8.22% YoY) and the FY2025 annual result came in at $2.8 million, down 8.06% from the prior year.
• Other Non-Current Liabilities declined to $2.8 million in Q1 2026 per PRLD's latest filing, from $2.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $3.4 million in Q4 2022 and troughed at $2.4 million in Q1 2022.
• A 5-year average of $3.1 million and a median of $3.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Other Non-Current Liabilities soared 40.04% in 2023, then declined 8.22% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $3.4 million in 2022, then declined by 0.65% to $3.3 million in 2023, then declined by 7.46% to $3.1 million in 2024, then slipped by 8.06% to $2.8 million in 2025, then slipped by 2.18% to $2.8 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $2.8 million, $2.8 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.